Literature DB >> 20494359

LXRalpha regulates human CETP expression in vitro and in transgenic mice.

Shoko Honzumi1, Akiko Shima, Ayano Hiroshima, Tadashi Koieyama, Naoko Ubukata, Naoki Terasaka.   

Abstract

Liver X receptors (LXRs), LXRalpha and LXRbeta, are members of the nuclear receptor superfamily and regulate the expression of genes involved in the regulation of cholesterol and fatty acid metabolism. Human plasma, unlike mouse plasma, contains cholesteryl ester transfer protein (CETP), which plays an important role in reverse cholesterol transport (RCT). LXRs induce CETP transcription via a direct repeat 4 element in the CETP promoter. However, the specific roles of the individual LXR subtypes in CETP expression and their consequences on plasma lipoprotein metabolism are still unclear. Here we showed that synthetic LXR agonist enhanced plasma CETP activity and resulted in non-high density lipoprotein (non-HDL) increase and HDL decrease in cynomolgus monkeys and human CETP transgenic mice. To address the relative importance of the two LXR subtypes, we investigated the effect of the suppression of both LXR subtypes on CETP expression in HepG2 cells. CETP expression induced by the LXR agonist was significantly reduced by LXRalpha knock-down, but not by LXRbeta. Consistent with these data, CETP promoter activity was enhanced by LXRalpha activation, whereas LXRbeta activation had only a minor effect. Furthermore, we investigated the effect of genetic deficiency of both LXR subtypes in human CETP transgenic mice. LXRalpha deficiency abolished the augmentation of plasma CETP activity and hepatic CETP expression induced by the synthetic LXR agonist, consequently increasing HDL and decreasing non-HDL, whereas LXRbeta deficiency did not affect CETP activation. These findings indicate that LXRalpha has an essential role in the regulation of CETP expression and maintaining RCT. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494359     DOI: 10.1016/j.atherosclerosis.2010.04.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.

Authors:  Cynthia Hong; Stephanie M Marshall; Allison L McDaniel; Mark Graham; Joseph D Layne; Lei Cai; Elena Scotti; Rima Boyadjian; Jason Kim; Brian T Chamberlain; Rajendra K Tangirala; Michael E Jung; Loren Fong; Richard Lee; Stephen G Young; Ryan E Temel; Peter Tontonoz
Journal:  Cell Metab       Date:  2014-11-04       Impact factor: 27.287

Review 3.  Cholesteryl ester transfer protein and its inhibitors.

Authors:  Sudichhya Shrestha; Ben J Wu; Liam Guiney; Philip J Barter; Kerry-Anne Rye
Journal:  J Lipid Res       Date:  2018-02-27       Impact factor: 5.922

Review 4.  Liver X receptors in lipid metabolism: opportunities for drug discovery.

Authors:  Cynthia Hong; Peter Tontonoz
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

5.  Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms: reduced expression associated with rs247616.

Authors:  Adam Suhy; Katherine Hartmann; Audrey C Papp; Danxin Wang; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

Review 6.  Role of liver X receptors in cholesterol efflux and inflammatory signaling (review).

Authors:  Rongtao Zhu; Zhibing Ou; Xiongzhong Ruan; Jianping Gong
Journal:  Mol Med Rep       Date:  2012-01-17       Impact factor: 2.952

7.  ABC Transporters and the Alzheimer's Disease Enigma.

Authors:  Andrea Wolf; Björn Bauer; Anika M S Hartz
Journal:  Front Psychiatry       Date:  2012-06-04       Impact factor: 4.157

8.  Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.

Authors:  Huub J van Eyk; Lisanne L Blauw; Maurice B Bizino; Yanan Wang; Ko Willems van Dijk; Renée de Mutsert; Johannes W A Smit; Hildo J Lamb; Ingrid M Jazet; Patrick C N Rensen
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

9.  Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.

Authors:  Akihiro Shimada; Hideki Kimura; Koji Oida; Hideo Kanehara; Yukihiro Bando; Shinobu Sakamoto; Takanobu Wakasugi; Takashi Saga; Yasuki Ito; Kazuko Kamiyama; Daisuke Mikami; Masayuki Iwano; Tsutomu Hirano; Haruyoshi Yoshida
Journal:  Lipids Health Dis       Date:  2016-03-17       Impact factor: 3.876

10.  Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.

Authors:  Sarah R Breevoort; Jerry Angdisen; Ira G Schulman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-19       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.